Advances in Epidermal Growth Factor Receptor-Driven Non-Small-Cell Lung Cancer: Diagnostic Technologies and Therapeutic Strategies

Dear Colleagues,

We are excited to announce a call for papers for a forthcoming Special Issue of our journal dedicated to diagnostic advances in epidermal growth factor receptor-targeted therapy for non-small-cell lung cancer. This Special Issue aims to spotlight the latest scientific research and advancements in the diagnosis and treatment of NSCLC, with a particular focus on the role of epidermal growth factor receptor (EGFR) targeting. 

We welcome submissions of original research papers and comprehensive review articles that contribute to, but are not limited to, the following areas:

1. Technology/Device Advancement in Diagnosis: Innovations in diagnostic technologies or devices that enhance the detection and understanding of NSCLC, especially those that facilitate EGFR-targeted therapy approaches.
2. Fundamental Biological Discovery: Breakthrough discoveries in the fundamental biology of NSCLC that significantly improve the diagnostic process. Submissions should focus on insights that pave the way for more effective EGFR-targeted diagnosis.
3. Clinical Practice/Procedure to Assist Diagnosis: Papers that explore new clinical practices or procedures that aid in the timely and accurate diagnosis of NSCLC, thereby facilitating better patient outcomes through EGFR-targeted therapies.
4. Combination of Diagnosis and Therapeutics: Research that examines the integration of diagnostic processes with therapeutic strategies to enhance the overall treatment outcome for NSCLC patients, including the role of EGFR targeting in treatment plans.
5. Computer- or AI-Assisted Diagnosis: Submissions that highlight the application of computer science or artificial intelligence in diagnosing NSCLC, particularly in improving the precision of EGFR-targeted therapy decisions.

This Special Issue aims to cover a broad spectrum of NSCLC stages, including early-stage cancer, advanced-stage cancer, and the monitoring of NSCLC throughout therapeutic treatment. We believe that the comprehensive understanding and innovative approaches presented in this Special Issue will significantly contribute to the advancement of NSCLC diagnosis and treatment, ultimately improving patient care and outcomes. 

Submission Guidelines:

• All submissions must be original work and not under consideration by other publications. 

• Articles should adhere to the journal's submission guidelines, available on our website. 

• Please indicate in your cover letter that your submission is for the special issue on "Advances in Epidermal Growth Factor Receptor-Driven Non-Small-Cell Lung Cancer: Diagnostic Technologies and Therapeutic Strategies”. 

We look forward to receiving your contributions and advancing the field of NSCLC diagnosis and treatment together. For any inquiries, please contact the Special Issue editors. 

Sincerely,

Dr. Fang Wei
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• EGFR-targeted therapy
• non-small-cell lung cancer diagnosis
• diagnostic technologies and devices
• biological discoveries in NSCLC
• AI-assisted diagnosis in oncology
• clinical practice in NSCLC detection
• therapeutic–diagnostic integration
• early-stage lung cancer monitoring
• advanced NSCLC diagnostic approaches
• precision medicine in lung cancer